Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

SPIKEVAX DIN 02541270

Status: Marketed
Holder: MODERNA BIOPHARMA CANADA CORPORATION
Molecule: *SARSCOV2 S-PROTEIN MRNA, 5'(M7G-5'-PPP-5'-GM), 3'POLYA

Health Canada record

Active ingredient(s)*SARSCOV2 S-PROTEIN MRNA, 5'(M7G-5'-PPP-5'-GM), 3'POLYA 0.1 MG
Dosage formDispersion
RouteIntramuscular
ScheduleSCHEDULE D
ClassHuman
ATCJ07BN01 COVID-19, RNA-BASED VACCINE
Original market date18-Sep-2023
Current status date17-Sep-2024
SourceHealth Canada DPD

Establishment licence of the holder

Moderna Biopharma Canada Corporation — licence 3-002801, currently licensed, last inspection rating C (2024-06-10).

No Canadian shortage report is currently matched to this DIN.

Other Canadian products containing *SARSCOV2 S-PROTEIN MRNA, 5'(M7G-5'-PPP-5'-GM), 3'POLYA

DINProductCompanyFormStrengthStatus
02557770SPIKEVAXMODERNA BIOPHARMA CANADA CORPORATIONDispersion*SARSCOV2 S-PROTEIN MRNA, 5'(M7G-5'-PPP-5'-GM), 3'POLYA 50 MCGMarketed
02568365SPIKEVAXMODERNA BIOPHARMA CANADA CORPORATIONDispersion*SARSCOV2 S-PROTEIN MRNA, 5'(M7G-5'-PPP-5'-GM), 3'POLYA 25 MCGApproved

Notices of Compliance

NOCDateSubmissionReason
315892023-09-12New Drug Submission (NDS)
Request a quote for SPIKEVAX

How to read a Canadian DIN record